Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.

MLA

Maeoka, Ryosuke, et al. “Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.” International Journal of Molecular Sciences, vol. 24, no. 18, Sept. 2023, p. 14183. EBSCOhost, https://doi.org/10.3390/ijms241814183.

APA

Maeoka, R., Nakazawa, T., Matsuda, R., Morimoto, T., Shida, Y., Yamada, S., Nishimura, F., Nakamura, M., Nakagawa, I., Park, Y.-S., Tsujimura, T., & Nakase, H. (2023). Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. International Journal of Molecular Sciences, 24(18), 14183. https://doi.org/10.3390/ijms241814183

Chicago

Maeoka, Ryosuke, Tsutomu Nakazawa, Ryosuke Matsuda, Takayuki Morimoto, Yoichi Shida, Shuichi Yamada, Fumihiko Nishimura, et al. 2023. “Therapeutic Anti-KIR Antibody of 1–7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.” International Journal of Molecular Sciences 24 (18): 14183. doi:10.3390/ijms241814183.